What do systematic reviews say?

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

The review found no eligible studies for this question.

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 131 participants
  Low

Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer

• Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 118 participants
  Very low

Single foetal haemoglobin inducer at any dose or duration vs placebo or usual care

It is very uncertain whether single foetal haemoglobin inducer at any dose or duration changes adverse events compared with usual care or placebo (very low certainty).

• Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 56 participants
  Very low

Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer

• Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 104 participants
  Very low